Which when defective.

A step closer to correcting unhealthy gene mutations with diet Analysis published in the Genetics Society of America’s journal Genetics runs on the new technique to determine which individuals with homocystinuria are most likely to respond to supplement B6 treatment based on their genotypesScientists have moved a step nearer to correcting some harmful gene mutations with diet plan, according to a new research report showing up in the April 2012 problem of the journal GENETICS ( Researchers from the University of California, Berkeley, determined variations and responses to vitamin treatment in the individual cystathionine beta synthase gene, which when defective, causes the condition homocystinuria, an inherited metabolic disorder treatable with vitamin B6 sometimes.The pre-clinical and clinical development has been backed by NIH SMALL COMPANY Innovation Study grants awarded to Aestus by the National Institute of Neurological Diseases and Stroke . Included in these are SBIR Phase I and II grants for over $2.5 million, which support the Phase 2 medical studies currently. Aestus can be filing an Investigational New Medication software with the meals and Drug Administration because of its business lead therapeutic, ATx08-001, in order to begin patient recruitment for clinical trials in the near future.